Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 32

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 32
---
 our intellectual property, particularly our trademarks,
patents and trade secrets to be of considerable value and importance to our business and our success. We rely on a combination of trademark,
patent, and trade secrecy laws, confidentiality procedures and contractual provisions to protect our intellectual property rights. There
can be no assurance that the steps taken by us to protect these proprietary rights will be adequate or that third parties will not infringe
or misappropriate our trademarks, patented processes, trade secrets or similar proprietary rights. In addition, there can be no assurance
that other parties will not assert infringement claims against us, and we may have to pursue litigation against other parties to assert
our rights. Any such claim or litigation could be costly. In addition, any event that would jeopardize our proprietary rights or any
claims of infringement by third parties could have a material adverse effect on our ability to market or sell our brands, profitably
exploit our products or recoup our associated research and development costs.

<div align='center'>15</div>

The patenting process, enforcement of issued patents, and defense against claims of infringement are inherently risky.

The strength of our
patent portfolio is an important factor that will influence our success. Securing patent approval for the ARB-based anti-cancer adjunct
drug candidate is essential to safeguard our investment and maintain a competitive position in the market. . Patents give the patent
holder the right to prevent others from using its patented technology. If someone infringes upon the patented material of a patent holder,
the patent holder has the right to initiate legal proceedings against that person to protect its patented material. These proceedings,
however, can be lengthy and costly. We perform an ongoing review of our patent portfolio to confirm that our key technologies are adequately
protected. If we determine that any of our patents require either additional disclosures or revisions to existing information, we may
ask that such patents be reexamined or reissued, as applicable, by the United States Patent and Trademark Office.

Because we rely heavily
on patent protection, we face the following significant risks:

| ● | Possibility of Inadequate                                                                                                                  
 Patent Protection for Product. The United States Patent and Trademark Office or foreign patent offices may not grant patents               
 of meaningful scope based on the applications we have already filed and those we intend to file. If we do not have patents that adequately 
 protect our human-use equipment and indications for its use, then we will not be competitive.                                              |

| ● | Potential That Important                                                                                                           
 Pat